0000000000753246

AUTHOR

Putzu C

showing 3 related works from this author

“OXXEL (Oxaliplatin plus Xeloda) versus OXAFAFU (Oxaliplatin plus folinic acid-modulated 5-fluorouracil i.v. bolus) every 2 weeks in metastatic color…

2006

researchProduct

“OXXEL (oxaliplatin plus Xeloda) vs OXAFAFU (oxaliplatin plus folinic acid-modulated 5-fluorouracil i.v. bolus) every 2 weeks in metastatic colorecta…

2006

researchProduct

“Comparison of the safety and efficacy of paclitaxel plus gemcitabine combination in young and elderly patients with locally advanced or metastatic n…

2008

We retrospectively assessed tolerability and efficacy of paclitaxel plus gemcitabine combination in 259 patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) enrolled in three randomized SICOG trials according to their age (70 years) at study entry. Apart from age, demographic and clinical characteristics were similar in the two groups. Response rate of paclitaxel plus gemcitabine was similar in younger and in elderly (36% versus 30%). Chemotherapy was well tolerated, but severe neutropenia (12% versus 7%), anaemia (6.6% versus 1.8%), and vomiting (5% versus 0) were more frequent in elderly patients. Both median progression-free survival (PFS, 5.5 months versus 4.2…

PaclitaxelNon-small cell lung cancerGemcitabineElderly patient
researchProduct